Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Alcohol Clin Exp Res ; 38(6): 1520-31, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24773203

ABSTRACT

BACKGROUND: Chronic alcohol intake affects liver function and causes hepatic pathological changes. It has been shown that peroxisome proliferator-activated receptor α (PPARα)-null mice developed more pronounced hepatic changes than wild-type (WT) mice after chronic exposure to a diet containing 4% alcohol. The remarkable similarity between the histopathology of alcoholic liver disease (ALD) in Ppara-null model and in humans, and the fact that PPARα expression and activity in human liver are less than one-tenth of those in WT mouse liver make Ppara-null a good system to investigate ALD. METHODS: In this study, the Ppara-null model was used to elucidate the dynamic regulation of PPARα activity during chronic alcohol intake. Hepatic transcriptomic and metabolomic analyses were used to examine alterations of gene expression and metabolites associated with pathological changes. The changes triggered by alcohol consumption on gene expression and metabolites in Ppara-null mice were compared with those in WT mice. RESULTS: The results showed that in the presence of PPARα, 3 major metabolic pathways in mitochondria, namely the fatty acid ß-oxidation, the tricarboxylic acid cycle, and the electron transfer chain, were induced in response to a 2-month alcohol feeding, while these responses were greatly reduced in the absence of PPARα. In line with the transcriptional modulations of these metabolic pathways, a progressive accumulation of triglycerides, a robust increase in hepatic cholic acid and its derivatives, and a strong induction of fibrogenesis genes were observed exclusively in alcohol-fed Ppara-null mice. CONCLUSIONS: These observations indicate that PPARα plays a protective role to enhance mitochondrial function in response to chronic alcohol consumption by adaptive transcriptional activation and suggest that activation of this nuclear receptor may be of therapeutic value in the treatment for ALD.


Subject(s)
Bile Acids and Salts/metabolism , Fatty Acids/metabolism , Liver Diseases, Alcoholic/metabolism , PPAR alpha/physiology , Animals , Ethanol/adverse effects , Fibrosis , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver Diseases, Alcoholic/pathology , Male , Metabolomics , Mice , Mitochondria, Liver/drug effects , Mitochondria, Liver/metabolism , Oligonucleotide Array Sequence Analysis , PPAR alpha/metabolism
2.
BMC Musculoskelet Disord ; 10: 46, 2009 May 01.
Article in English | MEDLINE | ID: mdl-19409094

ABSTRACT

BACKGROUND: A critical component of disease progression in rheumatoid arthritis (RA) involves neovascularization associated with pannus formation. 2-methoxyestradiol (2ME2) is a naturally occurring molecule with no known physiologic function, although at pharmacologic concentrations it has antiproliferative and antiangiogenic activities. We investigated the impact of orally administered 2ME2 on the initiation and development of proliferative synovitis using the anti-collagen monoclonal antibodies (CAIA) model. METHODS: Severe polyarticular arthritis was induced in Balb/c female mice by administration of 2 mg of a monoclonal antibody cocktail intravenously into the tail vein of mice. Twenty-four hours following monoclonal antibody administration, mice were injected with 25 microg of LPS (E. coli strain 0111:B4) via the intraperitoneal route. Treatment with 2ME2 (100, 75, 50, 25, 10, 1 mg/kg, p.o., daily), or vehicle control began 24 hrs following LPS challenge and continued to day 21. Hind limbs were harvested, sectioned and evaluated for DMARD activity and general histopathology by histomorphometric analysis and immunohistochemistry (vWF staining). In a separate study, different dosing regimens of 2ME2 (100 mg/kg; q.d. vs q.w. vs q.w. x 2) were evaluated. The effect of treatment with 2ME2 on gene expression of inflammatory cytokines and angiogenic growth factors in the joint space was evaluated 5 and 14 days after the induction of arthritis. RESULTS: Mice treated with 2ME2 beginning 24 hours post anti-collagen monoclonal antibody injection, showed a dose-dependent inhibition in mean arthritic scores. At study termination (day 21), blinded histomorphometric assessments of sectioned hind limbs demonstrated decreases in synovial inflammation, articular cartilage degradation, pannus formation, osteoclast activity and bone resorption. At the maximal efficacious dosing regimen (100 mg/kg/day), administration of 2ME2 resulted in total inhibition of the study parameters and prevented neovascularization into the joint. Examination of gene expression on dissected hind limbs from mice treated for 5 or 14 days with 2ME2 showed inhibition of inflammatory cytokine message for IL-1beta, TNF-alpha, IL-6 and IL-17, as well as the angiogenic cytokines, VEGF and FGF-2. CONCLUSION: These data demonstrate that in the CAIA mouse model of RA, 2ME2 has disease modifying activity that is at least partially attributable to the inhibition of neovascular development. Further, the data suggests new mechanistic points of intervention for 2ME2 in RA, specifically inhibition of inflammatory mediators and osteoclast activity.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Blood Vessels/drug effects , Estradiol/analogs & derivatives , Joints/drug effects , Neovascularization, Pathologic/drug therapy , 2-Methoxyestradiol , Angiogenesis Inhibitors/pharmacology , Angiogenesis Inhibitors/therapeutic use , Angiogenic Proteins/antagonists & inhibitors , Angiogenic Proteins/metabolism , Animals , Antibodies, Monoclonal/toxicity , Antirheumatic Agents/pharmacology , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/metabolism , Arthritis, Rheumatoid/physiopathology , Blood Vessels/pathology , Blood Vessels/physiopathology , Bone Resorption/drug therapy , Bone Resorption/pathology , Cartilage, Articular/drug effects , Cartilage, Articular/pathology , Cartilage, Articular/physiopathology , Cytokines/drug effects , Cytokines/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Estradiol/pharmacology , Estradiol/therapeutic use , Female , Joints/pathology , Joints/physiopathology , Mice , Mice, Inbred BALB C , Neovascularization, Pathologic/pathology , Neovascularization, Pathologic/physiopathology , Synovial Membrane/blood supply , Synovial Membrane/drug effects , Synovial Membrane/physiopathology , Synovitis/drug therapy , Synovitis/pathology , Synovitis/physiopathology , Time Factors , Treatment Outcome
3.
Int J Radiat Oncol Biol Phys ; 95(1): 131-138, 2016 May 01.
Article in English | MEDLINE | ID: mdl-26725728

ABSTRACT

PURPOSE: There are uncertainties associated with the prediction of colorectal cancer (CRC) risk from highly energetic heavy ion (HZE) radiation. We undertook a comprehensive assessment of intestinal and colonic tumorigenesis induced after exposure to high linear energy transfer (high-LET) HZE radiation spanning a range of doses and LET in a CRC mouse model and compared the results with the effects of low-LET γ radiation. METHODS AND MATERIALS: Male and female APC(1638N/+) mice (n=20 mice per group) were whole-body exposed to sham-radiation, γ rays, (12)C, (28)Si, or (56)Fe radiation. For the >1 Gy HZE dose, we used γ-ray equitoxic doses calculated using relative biological effectiveness (RBE) determined previously. The mice were euthanized 150 days after irradiation, and intestinal and colon tumor frequency was scored. RESULTS: The highest number of tumors was observed after (28)Si, followed by (56)Fe and (12)C radiation, and tumorigenesis showed a male preponderance, especially after (28)Si. Analysis showed greater tumorigenesis per unit of radiation (per cGy) at lower doses, suggesting either radiation-induced elimination of target cells or tumorigenesis reaching a saturation point at higher doses. Calculation of RBE for intestinal and colon tumorigenesis showed the highest value with (28)Si, and lower doses showed greater RBE relative to higher doses. CONCLUSIONS: We have demonstrated that the RBE of heavy ion radiation-induced intestinal and colon tumorigenesis is related to ion energy, LET, gender, and peak RBE is observed at an LET of 69 keV/µm. Our study has implications for understanding risk to astronauts undertaking long duration space missions.


Subject(s)
Gamma Rays/adverse effects , Heavy Ion Radiotherapy/adverse effects , Intestinal Neoplasms/etiology , Neoplasms, Radiation-Induced/etiology , Relative Biological Effectiveness , Animals , Carbon/adverse effects , Carbon/therapeutic use , Colonic Neoplasms/etiology , Female , Ferrous Compounds/adverse effects , Ferrous Compounds/therapeutic use , Gamma Rays/therapeutic use , Heavy Ion Radiotherapy/methods , Intestine, Small/radiation effects , Linear Energy Transfer , Male , Mice , Mice, Inbred C57BL , Radiotherapy Dosage , Sex Factors , Silicon/adverse effects , Silicon/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL